Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 8 Oct 18 – 24, 2026
- Disclosed funding
- $852.9M 5 disclosed amounts
- Median round
- $200M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| ST Star TherapeuticsCompany profile Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need. Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need. | $200M | Private financingUndisclosed | Biotech | United States | Investors | |
| PA Pathos AICompany profile Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials. Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials. | $237M | Series ESeries C+ | Biotech | United States | Investors | |
| WS Warp SciencesCompany profile Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States. Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States. | $215M | Series A | Biotech | United States | Investors | |
| S SEGNOSCompany profile SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing. SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing. | Undisclosed | Pre-Series AUndisclosed | Biotech | Japan | Investors | |
| i iCUREXCompany profile Kagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing. Kagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing. | ¥140M | Series A first close: equity and debtSeries A | Biotech, Healthtech | Japan | Investors | |
| W WarhoundCompany profile Warhound develops working dogs for military, law-enforcement and emergency-response teams. Warhound develops working dogs for military, law-enforcement and emergency-response teams. | $200M | Seed | Biotech, Defense tech | United States | Investors | |
| K Rice-based dairy alternatives and plant molecular-farming technology. | ¥490M | Series A first closeSeries A | Biotech, Foodtech | Japan | Investors | |
| N Clinical-stage biotech developing neoantigen-based cancer immunotherapies. | €120M | Series DSeries C+ | Biotech | Switzerland | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Oct 18, 2026
- 1Lux Capital
Warp Sciences, Warhound
2rounds0led - 2Bristol Myers Squibb
Pathos AI
1rounds1led - 3Janus Henderson Investors
Star Therapeutics
1rounds1led - 4OrbiMed
Star Therapeutics
1rounds1led - 58VC
Warhound
1rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.